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Background: The tumor suppressor p53 is frequently inactivated in 
non–small cell lung cancer (NSCLC). Activation of the p53 pathway 
by inhibition of its negative regulator MDM2 may offer an attractive 
approach for NSCLC therapy. We evaluated the antitumor activity 
of the small-molecule MDM2 inhibitor RG7388 in patient-derived 
xenograft (PDX) models of NSCLC.
Methods: We investigated the effect of RG7388 treatment on cell 
proliferation, cell cycle arrest, and apoptosis using a panel of human 
NSCLC cell lines (A549, H157, H1650, H1395, and H358) and PDX 
cell lines (human lung cell lines 12, 137, 277, and 196). PDX-bearing 
mice were used to test the therapeutic efficacy and pharmacodynamic 
effects of RG7388 treatment.
Results: We demonstrated that RG7388 promotes low nanomolar 
antiproliferative activity selectively in cell lines with wild-type p53 
and p53 pathway activation, resulting in cell cycle arrest and apop-
tosis. In PDX models, oral administration of RG7388 led to potent 
dose-dependent and time-dependent activation of p53 and had a 
significant impact on p53 downstream targets. Daily treatment of 
RG7388 in mice at 50 and 80 mg/kg/day inhibited tumor growth in 
three wild-type p53 PDX models. Activation of the p53 pathway 
inhibited cell proliferation as observed by reduced Ki-67-positive 
cells in xenograft tumors. However, induction of apoptotic caspase 
activity was not observed in these tumors. Notably, RG7388 treat-
ment remains effective in tumors lacking MDM2 amplification but 
expressing wild-type p53.
Conclusions: MDM2 small-molecule inhibitor is effective in treat-
ing NSCLC tumors with wild-type p53, supporting further clinical 
investigation as a potential NSCLC therapy.
Key Words: MDM2 inhibitor, p53, RG7388, Non–small cell lung 
cancer, Patient-derived xenografts.
(J Thorac Oncol. 2015;10: 1172–1180)
Lung cancer causes the greatest number of cancer deaths worldwide.1 Non–small-cell lung cancer (NSCLC) 
accounts for the majority of lung cancer cases, and the 5-year 
survival rate is only 16%.1–3 In the last decade, molecularly 
targeted drugs such as epidermal growth factor receptor 
(EGFR) and anaplastic lymphoma kinase (ALK) tyrosine 
kinase inhibitors have emerged as viable therapeutic options 
for lung adenocarcinoma patients.4,5 However, these two pro-
teins represent possible targets in only a fraction of NSCLC 
patients. Therefore, there is a need to investigate the efficacy 
of new agents directed against other potential driver onco-
genes in NSCLC.
The tumor suppressor p53 plays an important role in 
protecting against cancer development. The p53 protein is 
a transcription factor that prevents accumulation of genetic 
damage in response to stress by regulating DNA repair, the 
cell cycle, and apoptosis through transactivation of key down-
stream genes.6 The MDM2 gene is a direct transcriptional tar-
get of p53, which in turn is inhibited by binding of MDM2 at 
its N-terminal transactivation domain.7 MDM2 is also an E3 
ubiquitin ligase that ubiquitinates p53 at several lysine resi-
dues to target the protein for proteasome degradation.7,8
Inactivation of TP53 by mutation or deletion has been 
observed in approximately 50% to 80% of NSCLC patients.9,10 
Indeed, known tobacco carcinogens, such as benzo[a]pyrene, 
have been shown to form diol epoxide adducts at lung can-
cer mutation hotspots within the human TP53 gene.11 Almost 
80% of loss-of-function TP53 mutations are missense muta-
tions disrupting the p53 DNA-binding domain.12 Furthermore, 
even in the presence of functional p53, tumor cells can overex-
press MDM2 to reduce p53 activity by means of an autoregu-
latory feedback loop.13,14 Inhibition of p53-MDM2 interaction 
in tumor cells could be a potential strategy to restore p53 func-
tion and to counteract the oncogenic consequences of MDM2 
overproduction in NSCLC patients.
Members of the nutlin class of imidazole compounds 
interact specifically with the p53-binding pocket of MDM2 to 
free p53 from MDM2-mediated negative control.15 RG7112 
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was the first generation of this family to be assessed clinically.15 
Restoration of p53 function was observed after oral adminis-
tration of RG7112 to mice with tumors bearing human osteo-
sarcoma cells with MDM2 gene amplification.15 A neoadjuvant 
clinical study found partial response or stable disease in 15 of 
20 liposarcoma patients treated preoperatively with RG7112 for 
up to three 28-day cycles.16 End-of-study biopsies revealed that 
RG7112 treatment activated the p53 pathway and decreased 
cell proliferation.16 Building on the success of the discovery 
of RG7112, a second-generation pyrrolidine-based compound 
RG7388 with superior potency, has been developed.17
A common practice in preclinical drug evaluation is to 
test drug activity using mouse tumors formed by implanting 
established human tumor cell lines.18 However, cells trans-
planted after prolonged artificial in vitro culture typically lack 
the molecular and histological characteristics and heterogene-
ity of the original patient tumors.19,20 Because early-passage 
xenografts derived from fresh surgical tumor specimens are 
not cultured on plastic but are propagated in immune-deficient 
mice, these models may predict clinical response better than 
conventional cell line–derived tumors.21 Topp et al.22 reported 
that response to cisplatin in ovarian patient-derived xeno-
graft (PDX) models was consistent with clinical response in 
patients. In the present study, we demonstrate that the MDM2 
inhibitor RG7388 can reactivate p53 signaling and inhibit 
tumor growth in clinically relevant NSCLC PDX models 
expressing wild-type p53 in vitro and in vivo, supporting fur-
ther clinical evaluation of MDM2 inhibitors in NSCLC.
MATERIALS AND METHODS
Cell Lines and Reagents
Human NSCLC cell lines, NCI-A549, NCI-H1395, 
NCI-H157, NCI-H1650, and NCI-H358, were obtained from 
the American Type Culture Collection (Manassas, VA). All 
cells were cultured in RPMI medium supplemented with 
10% fetal bovine serum (Hyclone Europe, Ltd., Cramlington, 
United Kingdom) and antibiotics at 37°C and 5% carbon 
dioxide. Authentication of human cell lines was performed by 
short tandem repeat DNA profiling analysis.
NSCLC PDX models were established using protocols 
approved by the University Health Network Research Ethics 
Board and Animal Care Committee as previously described.21 
Human lung cell lines (HLC) 12, 277, 137, and 196 were 
derived from tumor fragments of PDX models grown in NOD-
SCID mice21 and were processed into a single-cell suspension to 
establish long-term cell culture growth on plastic dishes. Tumor 
fragments were minced, digested in collagenase for 1 hour at 
37°C, and treated with DNase for 10 minutes at 37°C. Magnetic 
columns (MACS Technology) coated with H2Kb/H2Dd anti-
mouse antibodies were used to deplete stromal mouse fibroblast 
cells in the tumor cell population. RG7388 and solvents were 
provided by Hoffmann-La Roche (Nutley, NJ).
Fluorescence In Situ Hybridization
Dual-color interphase fluorescence in situ hybridization 
was performed on 4-μm paraffin sections of tissue microarrays 
as previously described.23 Two bacterial artificial chromosome 
clones RP11-154P16 (starts 69,128,534 ends 69,309,251) 
and RP11-450G15 (starts 69,080,491 ends 69,256,798) 
that hybridize to the 12q15 region containing MDM2 (starts 
69,201,971 ends 69,239,320) were selected from the University 
of California Santa Cruz (UCSC) Human Genome Browser 
Assembly (February 2009 CRch37/hg19) and were obtained 
from the Centre for Applied Genomics (TCAG, Toronto, ON, 
Canada). The bacterial artificial chromosome clones were 
directly labeled with Spectrum Orange (SpO) fluorochrome 
using commercially available nick translation kit according 
to the manufacturer’s protocol and were used together with 
CEP12 control probe labeled with SpG (Abbott Molecular, 
Abbott Park, IL). Probes were verified on normal blood meta-
phases to confirm correct localization and on polymerase chain 
reaction (PCR). Probe numbers were counted in 50 nonover-
lapping tumor cells per core, and the scores were analyzed to 
determine the mean MDM2:CEP12 ratio per cell.
Western Blot Analysis and 
Immunohistochemistry
Whole-cell extracts were lysed with lysis buffer 
(10 mM Tris [pH 8.0], 1% NP-40, 2 mM ethylenediami-
netetraacetic acid, 150 mM, 0.1 mM Na
3
VO
4
, and protease 
inhibitors [Roche]), resolved by sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis and transferred to poly-
vinyliden fluoride membranes. Primary antibodies included 
anti-p53 (SC126; Santa Cruz, CA), anti-MDM2 (SMP14; 
Santa Cruz), p21 (C24420; BD Biosciences, Mississauga, 
ON), and beta-actin (Clone AC-74; Sigma, St. Louis, MI). 
After blocking, membranes were incubated with relevant anti-
bodies and probed with corresponding horseradish peroxi-
dase (HRP)-conjugated secondary antibodies (Cell Signaling, 
Beverly, MA). All films were developed with ECL-Plus 
reagents (GE Healthcare, Piscataway, NJ).
Formalin-fixed paraffin-embedded tissues were cut 
at 4-µm thickness and dried in a 60°C oven overnight. 
Immunohistochemistry was performed using the peroxidase 
antiperoxidase technique following a microwave antigen 
retrieval procedure. Ki-67 and cleaved caspase-3 antibodies 
were used at 1:500 dilution, and MDM2 and p53 were used at 
1:100 after pepsin digestion. Whole slides were scanned using 
the Aperio Scanscope XT (Vista, Canada). Tumor cells stained 
positive for Ki-67 were scored in 500 tumor cells. Similarly, 
cleaved caspase-3–positive cells were scored in 10 fields at 
high-power fields (×400 magnification). For MDM2- and 
p53-stained slides, pathologists (GA and SS) scored the slides 
using the hybrid (H) scoring method: H-score = % cells of 0 
intensity + (% cells of 1+ intensity × 1) + (% cells of 2+ inten-
sity × 2) + (% cells of 3+ intensity × 3). The intensity score 
was defined as 0 if no appreciable staining in the tumor cells; 
1+ barely detectable staining; 2+ readily appreciable brown 
staining distinctly marking the tumor cell cytoplasm and/or 
nucleus; and 3+ very strong dark staining in tumor cells.
Quantitative Real-Time PCR 
Analysis and DNA Sequencing
Total cellular RNA was extracted from xenograft 
tumors and cell lines using TRIzol reagent (Invitrogen, 
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Burlington, ON) and RNeasy Mini kit (Qiagen, Mississauga, 
ON), respectively. One microgram of total RNA was reverse 
transcribed using Superscript II RNase H reverse transcription 
kit (Invitrogen). Real-time quantitative PCR was performed 
with the human-specific primers listed in Supplementary 
Table S1 (Supplemental Digital Content, http://links.lww.
com/JTO/A845), and 10 ng of the first-strand cDNA synthesis 
as a template using Stratagene MX3000P and SYBR Green 
(Stratagene, La Jolla, CA). Messenger RNA (mRNA) copy 
number was adjusted by the geometric mean of the two house-
keeping genes ACTB and BAT1 as previously described.24 
Genomic DNA was extracted from xenograft tumors and cell 
lines using TRIzol reagent (Invitrogen). Using TP53 prim-
ers listed in Supplementary Table S1 (Supplemental Digital 
Content, http://links.lww.com/JTO/A845), PCR was used to 
prepare gene products for DNA sequencing.
Cell Viability, Cell Cycle, and Apoptosis Assays
Cell proliferation/viability was evaluated by the tetrazo-
lium dye (MTS) assay (Promega, Madison, WI). Each cell line 
was plated at a seeding density to give logarithmic growth over 
the course of the assay in a 96-well tissue culture plate. The 
concentration of final product was measured by absorbance 
at 490 nm, which is proportional to the viable cell number in 
each well. Apoptosis was determined using the Annexin V 
assay (Biolegend, San Diego, CA), and cell cycle was analyzed 
using the propidium iodide assay (Invitrogen, Waltham, MA). 
Cells were seeded in culture plates 24 hours before incubation 
with RG7388 for the indicated doses and times. Cells were 
collected and stained with Annexin V-FITC and/or propidium 
iodide solution as per the manufacturer’s protocol and analyzed 
by flow cytometry. Cell death was recorded in a FACSCanto 
II (BD Biosciences) in the total population (10,000 cells), and 
data were analyzed using FACSCanto II software and using 
ModFit Software (Verity Software House, Topsham, ME).
PDX Models
Non-obese (NOD)-SCID mice were bred on site at the 
Princess Margaret Cancer Centre animal facility. Mice were fed 
autoclaved food and water ad libitum. All manipulations were per-
formed under sterile conditions in a laminar flow hood, in accor-
dance with the procedures approved by the Institutional Animal 
Care Committee. PHLC 12, 189, 229, and 193 were revived by 
implanting cryopreserved early-passage tumor fragments (<6 
passages) into the subcutaneous tissue of the NOD-SCID mice. 
The histological subtype and mutational status for PDX models 
are listed in the Supplementary Table S3 (Supplemental Digital 
Content, http://links.lww.com/JTO/A845).
For treatment, mice were randomized into groups of six 
to 10 mice with similar mean tumor volumes of 50 to 150 mm3. 
RG7388 was administered by oral gavage at nontoxic doses from 
50 to 80 mg/kg daily (Supplementary Figure S1, Supplemental 
Digital Content, http://links.lww.com/JTO/A845). Tumor size 
was measured in two dimensions using a caliper every 3 to 4 
days. Tumor volume was calculated using the following for-
mula (length × width2)π/6. Mice were killed once the humane 
end point (approximately 1.5 cm diameter) was reached. At the 
time of killing, tumors were weighed and tumor portions were 
snap frozen and stored in liquid nitrogen or fixed in 10% buff-
ered formalin for routine histopathologic processing.
Statistics
All cell line and animal data are presented as mean ± stan-
dard error of the mean. Statistical significance was determined 
using two-tailed Student’s t test. Differences in tumor growth 
rates of xenografts were tested using mixed-model analysis of 
variance (ANOVA). Tests that produced p value 0.05 or less 
were considered to be significant. All statistical analyses were 
performed with GraphPad Prism 6.0 (La Jolla, CA).
RESULTS
RG7388 Activates p53 Pathway and Inhibits 
Cell Proliferation in p53 Wild-Type NSCLC Cells
RG7388 dose dependently induced p53 accumulation 
and up-regulation of the p53 downstream transcriptional tar-
gets p21 and MDM2 in multiple cell lines, including A549, 
H1395, and HLC 12 cells (Fig. 1A).
We next evaluated the ability of RG7388 to inhibit cell 
proliferation in five NSCLC cell lines (H1395, A549, H157, 
H1650, and H358) and four PDX-derived cell lines (HLC 12, 
277, 137, and 196). DNA sequencing of TP53 revealed that 
HLC 12 cells were wild type for TP53, whereas HLC 137, 196, 
and 277 cells harbored an S183stop and I251N and R337P 
mutation in the TP53 gene, respectively (Supplementary Table 
S2, Supplemental Digital Content, http://links.lww.com/JTO/
A845). Previous studies have reported that A549 and H1395 
are wild type for TP53 and H157, H1650, and H358 con-
tain c.892G>T, c.673-2A>G, and deletion in the TP53 gene, 
respectively.25
RG7388 potently inhibited cell growth in all three p53 
wild-type lines (HLC 12, A549 and H1395), giving rise to the 
half maximal inhibitory concentration (IC
50
) values ranging 
from 0.05 to 0.75 μM (Fig. 1B). In contrast, in the p53 mutant 
lines (H157, H1650, H358, HLC 137, HLC 196, and HLC 
277), treatment induced a 20- to 1000-fold lower cytotoxicity, 
with IC
50
 values ranging from 16 to 50 μM (Fig. 1C). RG7388 
induced the greatest response in the H1395 cell line, which har-
bors an MDM2 gene amplification (IC
50
: 0.05 μM).
RG7388 Induces Cell Cycle Arrest 
and Apoptosis in NSCLC Cells
One of the primary cellular functions of activated p53 
is inhibition of cell cycle progression in G1 and G2 phases. 
Treatment of exponentially proliferating A549 cells with 
RG7388 for 24 hours led to a dose-dependent cell cycle block 
in G1 and G2/M phases and a depletion of the S-phase com-
partment. At 1.5 μM concentration, the cell population in 
S-phase decreased from approximately 37% to 2%, whereas 
accumulation of cells at G1 and G2 phases increased (approx-
imately 49% to 74% and 14% to 24%, respectively; Fig. 2A). 
The same effect was observed in HLC 12 and H1395 cell line 
models, which showed a reduction of the S-phase population 
to 2% and 6%, respectively (Fig. 2B, C).
We then examined the effect of p53 activation on apopto-
sis in A549, HLC 12, and H1395 cells. In A549 cells, apoptosis 
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was significantly induced after 48 hours treatment of 1 to 10 μM 
of RG7388 (Fig. 2D). The concentration of RG7388 required 
to achieve 50% of the maximum cell cycle arrest (IC
50
: 0.75 
μM) was approximately seven-fold lower than the concentra-
tion required to induce apoptosis (IC
50
: >5 μM). In HLC 12 and 
H1395 cells, RG7388 induced a minor 1.5-fold increase in cell 
death at 10 and 5 μM, respectively (Fig. 2E, F).
RG7388 Activates the p53 Pathway 
in PDX Tumors In Vivo
Pharmocodynamic effects of RG7388 were assessed in 
mice bearing PHLC 12 and PHLC 189 tumors. Because pre-
vious reports have shown that osteosarcoma tumors with high 
levels of MDM2 protein or amplification are highly sensitive 
to RG7112, we examined the MDM2 amplification status in 
our PDX models.15 Using fluorescence in situ hybridization, 
MDM2 copy number (MDM2/CEP12 ratio per cell) for PHLC 
12 and PHLC 189 tumor was determined to be 1.04 and 
1.06, respectively (Supplementary Figure S2, Supplemental 
Digital Content, http://links.lww.com/JTO/A845). Similarly, 
silver-enhanced in situ hybridization assays determined that 
MDM2 copy number for PHLC 12 and PHLC 189 tumor to 
be 1.10 and 1.57, respectively (Supplementary Figure S3, 
Supplemental Digital Content, http://links.lww.com/JTO/
A845). These results were corroborated by the nuclear MDM2 
protein levels in PHLC 12 (H-score 80) and 189 xenograft 
tumor sections (H-score of 120; Fig. 3A, B).
We further verified that both xenograft models harbored 
wild-type p53 by sequencing the TP53 gene and immunohis-
tochemistry analysis (Fig. 3B and Supplementary Table S3, 
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FIGURE 1.  RG7388 activates p53 pathway and inhibits cell proliferation in p53 wild-type NSCLC and HLC cells. A, RG7388 
dose dependently accumulates p53 protein and its transcriptional targets MDM2 and p21 in A549, H1395, and HLC 12 cells. 
Western blot analysis was performed on whole-cell lysates 24 hours after RG7388 treatment. B, Three wild-type p53 and (C) 
six mutant p53 exponentially growing cell lines were incubated with RG7388 for 5 days, and cell viability was measured by 
MTS assay. Results represent means ± standard error of the mean from three independent experiments in quadruplicates. D, 
RG7388 cytotoxicity depends on the p53 status of lung cancer cells. E, Basal MDM2 protein levels were compared in cell lines 
by Western blot analysis. HLC, Human lung cell lines; NSCLC, non–small-cell lung cancer; MW, molecular weight.
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Supplemental Digital Content, http://links.lww.com/JTO/
A845). To examine the ability of RG7388 to activate the p53 
pathway in vivo, mice bearing these primary xenograft tumors 
were treated with a single oral dose of 50 or 80 mg/kg of 
RG7388 for 4, 8, or 24 hours. Western blot analysis showed a 
dose-dependent increase in p53 protein and its transcriptional 
targets, p21 and MDM2 (Fig. 3C, D). For PHLC 189 tumors 
treated with 50 mg/kg RG7388, p53 protein levels increased 4 
hours after treatment, peaked at 8 hours, and returned to basal 
levels by 24 hours. However, at the higher 80 mg/kg dose, p53 
levels increased after 4 hours and remained elevated after 24 
hours. Elevated levels of p21 and MDM2 accompanied these 
changes in p53 levels. Similarly, p53 and MDM2 protein lev-
els in PHLC 12 tumors peaked at 8 hours and persisted up to 
24 hours after dosing at both 50 and 80 mg/kg concentrations 
(Fig. 3D).
RG7388 Suppresses PDX Tumor Growth in Mice
We next tested the antitumor activity of RG7388 on 
mice bearing PHLC 189, 12, and 229 PDX models. Daily 
oral administration of RG7388 80 mg/kg significantly inhib-
ited PHLC 189 xenograft tumor growth rate (Fig. 4A). At 
the time of killing, tumors treated with RG7388 weighed 
approximately 50% less than the vehicle-treated group 
(p = 0.0002; Fig. 4A). Treatment with RG7388 for 28 days 
suppressed tumor growth (baseline 107 ± 9; post-treatment 
109 ± 13 mm3), whereas the vehicle-treated tumors grew 
from to 105 ± 11 to 217 ± 43 mm3. We also observed sig-
nificant growth suppression upon chronic administration of 
RG7388 on mice bearing PHLC 12 and PHLC 229 (Fig. 4B 
and C; p < 0.0001). In PHLC 12-bearing mice, equivalent 
antitumor response was achieved at both 80 and 50 mg/kg 
doses, suggesting that a lower dose regimen may be suf-
ficient to achieve the same efficacy despite more transient 
pharmacodynamics effects (Fig. 4B).
To evaluate the ability of RG7388 to induce cellular 
arrest or apoptosis in vivo, levels of the cell proliferation 
marker Ki-67 and the apoptotic marker cleaved caspase-3 
were measured in PHLC 189 tumors 24 hours after dosing 
with a single 80 mg/kg dose compared with vehicle alone 
(n = 8 per group; Fig. 5A). We detected significantly reduced 
(on average 30%) numbers of Ki-67-positive tumor cells in 
the RG7388-treated tumors compared with its control (39%; 
p = 0.0149; Fig. 5B). However, we did not detect a significant 
difference in the number of cleaved caspase-3–stained cells 
between groups (Fig. 5C).
To confirm that p53 accumulation was due to decreased 
degradation of the protein rather than elevated transcrip-
tion of the p53 gene, quantitative real-time PCR was con-
ducted on RNA extracted from PHLC 12 and PHLC 189 
after final RG7388 dosing. RG7388 significantly increased 
mRNA levels of genes: p21, GADD45, MDM2, and PUMA, 
which are known transcriptional p53 targets14 (Fig. 6A and 
Supplementary Figure S4, Supplemental Digital Content, 
A
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FIGURE 2.  RG7388 induces cell cycle arrest and apoptosis. A–C, Cell cycle analysis was analyzed by PI staining after treatment 
of A549 (A), HLC 12 (B), and H1395 (C) cells with indicated doses of RG7388 or DMSO for 24 hours. D–F, Apoptotic activity 
was measured by Annexin V and PI staining after incubation of A549 (D), HLC 12 (E), and H1395 (F) cells with indicated doses 
of RG7388 for 48 hours. Results represent mean ± standard error of the mean from three independent experiments (*p < 0.05; 
**p < 0.01; ****p < 0.0001). ns, not significant; HLC, human lung cell lines; PI, propidium iodide.
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http://links.lww.com/JTO/A845). In contrast, the level of 
the p53 transcript itself was unaffected by RG7388, sug-
gesting that RG7388 up-regulates p53 by means of a post- 
translational mechanism (Fig. 6A). Immunohistochemical 
detection of p53 protein levels in PHLC 12 and 229 dem-
onstrated the increased p53 nuclear accumulation in the 
RG7388-treated tumors compared with controls (p = 0.0120; 
Fig. 6B, C; Supplementary Figure S5, Supplemental Digital 
Content, http://links.lww.com/JTO/A845).
To confirm that the tumor inhibition was not due to 
p53-independent mechanisms induced by RG7388 exposure, 
we treated PHLC 193 mice harboring a R283H mutation in 
TP53 and MDM2 amplification (MDM2/CEP12: 8.88) with 
50 and 80 mg/kg of RG7388 for 1 week and found no tumor 
growth changes (Fig. 4D).
DISCUSSION
In this article, we demonstrate that blocking the p53-
MDM2 interaction using the small-molecule MDM2 inhibitor 
RG7388 can reactivate p53 in NSCLC cells, resulting in cell 
cycle arrest and apoptotic effects. Treatment of mice bearing 
PDX tumors with RG7388 led to the accumulation of p53 and 
significant inhibition of tumor growth, supporting the notion 
that established NSCLC tumors remain persistently vulner-
able to the p53 tumor suppressor function.26 These results pro-
vide compelling evidence that a single oral dose of RG7388 
is highly effective in activating p53 and its major function in 
cell cycle arrest.
The nutlin class of small-molecule MDM2 inhibitors 
have been reported to inhibit the proliferation of a variety of 
standard cancer cell lines with wild-type p53.17 This is the 
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first study to report RG7388 efficacy in a panel of NSCLC 
cells including cells derived from early-passage PDX mod-
els (HLC). Given that mutant p53 protein is unable to bind to 
DNA to exert its normal function, we expected that the growth 
inhibition and cytotoxic effects of RG7388 would be depen-
dent on the p53 status of NSCLC cells. Indeed, our data con-
firm that RG7388 potently and selectively inhibits cell growth 
in a panel of NSCLC and HLC cells harboring wild-type 
p53 and not in p53 mutant cells. RG7388 induced the great-
est response in the H1395 cell line, which harbors an MDM2 
gene amplification. This result is consistent with previous 
studies showing that RG7112, the first generation of this class 
of drug, was most effective in selectively killing osteosarcoma 
cell lines with MDM2 gene amplifications.15
One of the major functions of p53 is to suppress cell cycle 
progression, which typically precedes the induction of apoptosis. 
Our data show that A549, HLC 12, and H1395 cells undergo cell 
cycle block at G1 phase after treatment with RG7388 in a dose-
dependent manner. However, the onset of cell death was relatively 
slow compared with growth suppression. A much lower RG7388 
concentration was required to reach maximum cell cycle inhibi-
tion in A549 compared with maximum apoptotic activity. This 
was expected given that cell cycle arrest is one of the primary 
functions of p53 to protect cells from propagation of damaged 
DNA, whereas apoptosis is the ultimate step for elimination of 
cells with unrepairable damage.27 The lower drug threshold for 
cell cycle arrest in some cell lines may allow for delineation of 
the two effects of activated p53 in the clinical setting.
An important factor when considering drug combina-
tions with RG7388 is cell cycle–mediated drug resistance. 
The effects of antimetabolite drugs, such as gemcitabine, are 
cell cycle dependent, in that they are most effective during a 
specific part of the cell cycle.28 For example, gemcitabine is a 
nucleoside analogue incorporated into DNA to induce chain 
termination during S-phase.28 Previous studies have shown 
that mitogen-activated protein kinase kinase (MEK) 1 and 2 
inhibitors inhibitors suppress DNA synthesis and antagonize 
the effect of gemcitabine.28 Therefore, appropriate sequencing 
of the drug combinations with RG7388 should be considered 
when MDM2 inhibitor is being evaluated for clinical use.
In this article, we demonstrate the first in vivo efficacy of 
RG7388 in a panel of patient-derived NSCLC xenograft mod-
els, which closely mirror the histology and molecular profiles 
of the original patient tumors and may, therefore, be stronger 
predictors of clinical response.21 Previous in vivo evaluations 
of this class of nutlin imidazole compounds have been reported 
only in standard cell line–derived mouse models.17,29 We show 
that daily oral administration of RG7388 on PHLC 12-, 189-, 
and 229-bearing mice resulted in significant tumor growth 
inhibition. As predicted by the mechanistic model of p53 regu-
lation, antitumor effects resulted from decreased cell prolif-
eration as indicated by up-regulation of cell cycle genes p21 
and GADD45 and reduced Ki-67-positive proliferative cells in 
treated tumor sections compared with controls. Cleaved cas-
pase-3 detection is often used as a marker for apoptotic induc-
tion.30 However, in vivo caspase activity was not observed in 
either PHLC 12 or 189 xenografts. The presence of activated 
caspase 3 is viewed as an “early” marker of apoptosis, as it 
is often detected before plasma membrane blebbing and DNA 
fragmentation. Therefore, it is possible that most of the apop-
totic cells were eliminated before detection. Our in vivo data 
show that RG7388 treatment can elevate transcript levels of the 
downstream proapoptotic gene PUMA in both PHLC 12 and 
189 tumors. Therefore, it is conceivable that RG7388 may also 
induce caspase-independent mechanisms of cell death.
Previous studies have demonstrated that MDM2-
amplified osteosarcoma cells are highly sensitive to RG7112, 
suggesting that MDM2 gene amplification could be a use-
ful predictor of RG7112 response.15 In this article, we found 
potent antitumor response to RG7388 in both MDM2-amplified 
(H1395) and nonamplified (A549 and HLC12) NSCLC cells 
with wild-type p53. Functional p53 activation and significant 
tumor growth inhibition was observed in all three nonampli-
fied MDM2 PDX models upon RG7388 treatment. Consistent 
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FIGURE 6.  RG7388 activates p53 pathway and its downstream targets in vivo. A, Quantitative real-time PCR was performed 
on total tumor RNA extracted at 4 hours after treatment on PHLC12 mice to measure transcript levels of indicated genes rela-
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with this, a phase-1 RG7112 dose escalation study in sarcoma 
patients recently observed disease control and p53 biomarker 
activity in both MDM2-amplified and nonamplified patients.31 
MDM2 gene amplification is detected in 6% to 8% of lung 
adenocarcinomas and is uncommon in squamous cell car-
cinoma.9,10 Although it may be ideal to select patients with 
MDM2-amplified lung adenocarcinoma with wild-type p53 for 
RG7388 treatment, our data suggest that the use of p53 wild-
type status will identify a larger cohort of NSCLC patients who 
may respond and benefit from RG7388 treatment.
Clinical antitumor activity has been demonstrated recently 
with the first pharmacological MDM2 inhibitor RG7112 in 
liposarcoma patients.16 Here, using RG7388, a second-gener-
ation MDM2 antagonist with superior selectivity and potency, 
we demonstrated that RG7388 stimulates rapid p53 accumula-
tion in clinically relevant NSCLC PDX tumor models, resulting 
in inhibition of cell proliferation and tumor growth. This is the 
first study to provide strong support for the clinical evaluation 
of MDM2 small-molecule inhibitors in NSCLC patients and 
suggests that p53 wild-type status may be a useful predictor of 
response to p53-activating therapy by this class of agents.
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